Generation Bio CoNASDAQ:GBIO
- LAST PRICE1.4400
- TODAY'S CHANGE (%)0.0400 (2.8571%)
- Bid / Lots1.3700/ 1
- Ask / Lots1.7000/ 7
- Open / Previous Close1.4000 / 1.4000
- Day Range
- 52 Week Range
- Volume77,250
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | GBIO |
|---|---|---|
| 09:32 ET | 879 | 1.4 |
| 09:48 ET | 200 | 1.44 |
| 09:50 ET | 1360 | 1.435 |
| 09:55 ET | 2185 | 1.37 |
| 10:11 ET | 100 | 1.38 |
| 10:22 ET | 3521 | 1.385 |
| 10:24 ET | 600 | 1.38 |
| 10:27 ET | 100 | 1.38 |
| 10:33 ET | 1125 | 1.383 |
| 10:36 ET | 100 | 1.38 |
| 10:38 ET | 1872 | 1.3707 |
| 10:40 ET | 100 | 1.375 |
| 10:42 ET | 100 | 1.375 |
| 10:44 ET | 500 | 1.375 |
| 10:51 ET | 300 | 1.38 |
| 10:58 ET | 641 | 1.4 |
| 11:05 ET | 100 | 1.4 |
| 11:07 ET | 100 | 1.4 |
| 11:09 ET | 1031 | 1.409 |
| 11:16 ET | 500 | 1.39 |
| 11:21 ET | 200 | 1.4 |
| 11:25 ET | 200 | 1.41 |
| 11:34 ET | 435 | 1.43 |
| 11:36 ET | 500 | 1.43 |
| 11:38 ET | 5700 | 1.43 |
| 11:39 ET | 100 | 1.43 |
| 11:41 ET | 598 | 1.435 |
| 11:48 ET | 200 | 1.44 |
| 11:54 ET | 100 | 1.45 |
| 11:56 ET | 800 | 1.45 |
| 11:59 ET | 1977 | 1.4546 |
| 12:10 ET | 100 | 1.46 |
| 12:12 ET | 100 | 1.465 |
| 12:15 ET | 200 | 1.4671 |
| 12:19 ET | 600 | 1.46 |
| 12:21 ET | 833 | 1.47 |
| 12:26 ET | 300 | 1.47 |
| 12:30 ET | 500 | 1.47 |
| 12:35 ET | 363 | 1.47 |
| 12:42 ET | 600 | 1.46 |
| 12:44 ET | 100 | 1.47 |
| 12:51 ET | 100 | 1.47 |
| 12:53 ET | 100 | 1.47 |
| 12:57 ET | 100 | 1.48 |
| 01:04 ET | 100 | 1.47 |
| 01:15 ET | 100 | 1.48 |
| 01:42 ET | 100 | 1.47 |
| 01:44 ET | 200 | 1.47 |
| 01:51 ET | 100 | 1.47 |
| 01:56 ET | 400 | 1.47 |
| 02:02 ET | 100 | 1.475 |
| 02:05 ET | 1000 | 1.4701 |
| 02:07 ET | 305 | 1.4799 |
| 02:12 ET | 180 | 1.48 |
| 02:18 ET | 1000 | 1.46 |
| 02:23 ET | 100 | 1.45 |
| 02:36 ET | 200 | 1.4403 |
| 02:50 ET | 100 | 1.45 |
| 02:57 ET | 100 | 1.45 |
| 03:01 ET | 200 | 1.45 |
| 03:03 ET | 300 | 1.45 |
| 03:08 ET | 100 | 1.45 |
| 03:10 ET | 400 | 1.45 |
| 03:15 ET | 1000 | 1.455 |
| 03:26 ET | 100 | 1.45 |
| 03:32 ET | 700 | 1.435 |
| 03:33 ET | 500 | 1.43 |
| 03:35 ET | 100 | 1.44 |
| 03:37 ET | 368 | 1.43 |
| 03:46 ET | 4901 | 1.43 |
| 03:48 ET | 500 | 1.44 |
| 03:50 ET | 1900 | 1.45 |
| 03:51 ET | 300 | 1.45 |
| 03:55 ET | 200 | 1.46 |
| 03:57 ET | 627 | 1.45 |
| 04:00 ET | 13927 | 1.44 |
Nov 6, 2024
Generation Bio Reports Recent Business Highlights and Third Quarter 2024 Financial Results, from 4:05PM ET on Wednesday Nov 06, 2024 by Dow Jones
4:05PM ET on Wednesday Nov 06, 2024 by Dow Jones*DJ Generation Bio 3Q Loss/Shr 23c >GBIO, from 4:05PM ET on Wednesday Nov 06, 2024 by Dow Jones
4:05PM ET on Wednesday Nov 06, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Generation Bio Co | 91.5M | -0.7x | --- |
Adlai Nortye Ltd | 97.0M | -0.3x | --- |
Assembly Biosciences Inc | 95.6M | -2.0x | --- |
Coya Therapeutics Inc | 108.6M | -9.2x | --- |
Armata Pharmaceuticals Inc | 81.4M | -1.9x | --- |
CervoMed Inc | 79.2M | -5.0x | --- |
Company Information
Generation Bio Co. is a biotechnology company. The Company is innovating non-viral genetic medicines to provide durable, redosable treatments for hundreds of millions of patients living with rare and prevalent diseases. The Company is developing two distinct and complementary platforms: a potent, highly selective cell-targeted lipid nanoparticle (ctLNP) delivery system and a novel immune-quiet DNA (iqDNA) cargo produced by a scalable capsid-free manufacturing process that uses proprietary cell-free rapid enzymatic synthesis (RES). The Company is advancing a portfolio of programs guided by the potent and highly selective delivery of messenger ribonucleic acid (mRNA) and/or iqDNA using its ctLNP delivery system to target T cells, hematopoietic stem cells (HSCs), and hepatocytes, and intend to expand to additional tissues and cell types. Its work in T cells focuses on in vivo reprogramming of this cell type to treat cancer and autoimmune diseases.
Contact Information
- Headquarters
- 301 BINNEY STREETCAMBRIDGE, MA, United States 02142
- Phone
- 857-529-5908
- Fax
- 302-655-5049
Executives
- Independent Chairman of the Board
- Jason Rhodes
- President, Chief Executive Officer, Director
- Cameron Mcdonough
- Chief Financial Officer
- Matthew Norkunas
- Chief Operating Officer
- Antoinette Paone
- Chief Scientific Officer
- Matthew Stanton
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $91.5M |
|---|---|
Revenue (TTM) | $18.6M |
Shares Outstanding | 66.8M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 2.68 |
EPS | $-2.19 |
Book Value | $3.07 |
P/E Ratio | -0.7x |
Price/Sales (TTM) | 4.9 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -846.24% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
